Physician profile
Jerry John
NPI 1659440543
$7,684.81
in general payments reported to CMS, 2019-2025
13 companies · $1,004 in 2025
The $1,004 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,291 · 2021: $1,785 · 2022: $2,700 · 2023: $487 · 2024: $417 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381 · Travel and Lodging: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.15 |
| Travel and Lodging | $527.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,799.32 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Boston Scientific Corporation | $1,183.75 | 2019 | |
| Abiomed | $651.25 | 2024-2025 | Impella |
| Baxter Healthcare | $300.00 | 2021 | |
| Kestra Medical Technology Services, INC. | $203.64 | 2025 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $187.26 | 2025 | Uptravi, Opsumit, Opsynvi |
| Cardiac Dimensions, INC. | $166.17 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.53 | 2023 | |
| United Therapeutics Corporation | $24.08 | 2021 | |
| Pfizer INC. | $20.61 | 2025 | |
| Bard Peripheral Vascular, INC. | $19.55 | 2021 | |
| Janssen Biotech, INC. | $13.72 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.